Protein Sciences

Webinar title:

Innovative Production and Engineering Strategies for Fab, ScFv & VHH

Abstract:

Antibody fragments like Fab, ScFv, and VHH are emerging stars in antibody drug development, utilized both as standalone molecules and as building blocks of bispecific antibodies. However, their production and engineering face numerous challenges, including issues related to yield, purity, throughput, and stability. In this webinar, we will unveil innovative strategies to overcome these challenges, tailored to the distinctive characteristics of Fab, ScFv, and VHH. We’ll provide key insights into molecular design, high-titer CHO transient and stable pool production, and effective purification methods to accelerate your development of antibody fragments.

In this webinar, you will learn:

• Novel strategies to tackle common production challenges like low yields, throughput issues, and impurities in antibody fragment production.
• Advanced molecule engineering and linker design to mitigate aggregation and increase yield.
• Tailored approaches for optimizing the production of Fab, ScFv, and VHH, with a focus on specific strategies for each fragment type.

Speakers:

Jiansheng Wu, Ph.D., Vice President, Protein Sciences

Register Now

Webinar title:

Groundbreaking Innovations: High-Titer CHO Expression of Mini Proteins & T-Cell-Related Proteins

Abstract:

As the demand for novel biologic drug modalities continues to rise, mini proteins and T-cell-related proteins are emerging as promising candidates. However, the production of these proteins for biologics development has posed numerous challenges. Join our upcoming webinar to explore two groundbreaking platforms that overcome common challenges and are revolutionizing the production of mini proteins and T-cell-related proteins, significantly accelerating biologics development.

In this webinar, you will learn:

• How the Mini Protein Line surpasses traditional E. coli methods, utilizing high-titer CHO system to enhance expression and achieve extra-low endotoxin levels.
• How the T-Cell Mate platform efficiently produces challenging T-cell-related proteins, including sTCR, TCR-Ab fusions and SCT, enabling high throughput and yields critical for advancing therapeutic proteins.
• Case studies demonstrating the successful use of these innovative platforms in producing high-purity mini proteins and T-cell-related proteins.

Speakers:

Jiansheng Wu, Ph.D., Vice President, Protein Sciences

View Recording

Webinar title:

Innovative Platforms for Rapid and Cost-Effective HTP Antibody & Protein Production

Abstract:

As the field of biologics development evolves rapidly, there is increasing demand for high-throughput (HTP) antibody and protein production that is fast and cost-effective. This webinar showcases two innovative HTP antibody and protein production platforms: Ultra 96 and 777. Both platforms are powered by our ultra-high titer transient CHO system and designed for fast, affordable production. The Ultra 96 platform, with its 96- and 24-DWP format, quickly produces hundreds to thousands of antibodies per run at 100-1,500 µg each. The 777 offers low endotoxin and aggregates antibody production at 1-100 mg scale. Each platform addresses challenges at different stages of drug discovery, accelerating your drug development journey.

In this webinar, you will learn:   

• How the Ultra 96 and 777 platforms combine speed, purity, and scalability to streamline the biologics discovery process.
• Strategies for efficient high-throughput antibody/protein production that align with current trends and demands in biologic drug development.
• Case studies that demonstrate the successful application of Ultra 96 and 777 platforms in producing a large number of biologics rapidly and cost-effectively.

Speakers:

Julia Su, Ph.D., Associate Director, Protein Sciences

View Recording

Webinar title:

Assessing Pharmacokinetics and Manufacturability in Early Biologics Drug Discovery Webinar

Abstract:

In the early stages of biologics drug discovery, it’s crucial to have assays that reliably correlate with human pharmacokinetics (PK) and manufacturability. In this webinar, we introduce our advanced high-throughput analytical suite, designed to assess critical developability parameters. This comprehensive approach incorporates both in silico tools and diverse in vitro assays, including AC-SINS, Baculovirus/DNA/insulin ELISA, FcRn binding, Serum stability and others. Our panel is formatted in a 96WP design and requires only ~100ug of sample per assay, making it particularly suitable for the early lead ID/lead op stages.

You will gain valuable insight into:   

• How an integrated suite of developability assays can help evaluate the suitability of biologics as potential drugs at an early stage
• How these micro developability tests use minimal material (<1 mg of protein) to allow lead molecules to be examined at an earlier stage.
• Case studies demonstrating how these  developability tests reliably correlate with human PK and manufacturability.

Speakers:

Han Yang, Assistant Director, Protein Sciences

View Recording

Webinar title:

Unlock the Optimal Pairings of Bispecific Antibody Through Small Scale HTP BsAb Production & Efficient Scale-up Strategies

Webinar Abstract:

Join us for an exclusive webinar where the groundbreaking strategies for the bispecific antibody production will be presented, transforming your antibody drug discovery efforts. Bispecific antibody production entails challenges like heterogeneity, production complexity, and stability issues, impacting the quality of the final product. In this webinar, our esteemed industry expert will introduce innovative strategies and solutions to address challenges, spanning from small-scale high-throughput screening of a vast number of bispecific antibody pairings to large-scale production. Real-world case studies will showcase the successful application of these strategies.

During the webinar, you will gain valuable insight into:

1. Novel strategies for optimizing the production of bispecific antibodies in drug development.
2. An innovative high throughput production platform to quickly screen the optimal pairings of bispecific antibody for accelerated discovery.
3. Cutting-edge technologies for large scale production of bispecific antibodies.

Speakers:

Jiansheng Wu, Ph.D., Head of BioDev Protein Sciences Department

View Recording